Literature DB >> 10338102

Piracetam: novelty in a unique mode of action.

W E Müller1, G P Eckert, A Eckert.   

Abstract

Extensive research of the recent years has demonstrated that piracetam is effective in the treatment of cognitive decline in aging and dementia. It is usually much more active in situations of impaired brain function. Accordingly, its mechanism of action has been associated with neurochemical deficits of the aged brain relevant to cognitive dysfunctions. Since many of these neurochemical deficits depend on changes of membrane properties, including fluidity, it is of special importance that piracetam not only modifies membrane properties by interacting with the polar head moieties of the phospholipid bilayer, but also that this effect is more pronounced in membranes of aged as opposed to young animal and human brains, and that this mechanism also has specific relevance for brain membranes of Alzheimer's disease patients. Altering membrane properties might also be involved in vascular effects of piracetam such as improved erythrocyte deformability and normalization of hyperactive platelet aggregation. This novel mechanism of piracetam thus combines a rather non-specific physico-chemical mode of action with the pharmacological and clinical experience with this unique drug - effects are always much more pronounced when function is impaired.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10338102     DOI: 10.1055/s-2007-979230

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  19 in total

Review 1.  [Present status and future possibilities of adjuvant pharmacotherapy for aphasia].

Authors:  C Korsukewitz; C Breitenstein; M Schomacher; S Knecht
Journal:  Nervenarzt       Date:  2006-04       Impact factor: 1.214

Review 2.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

3.  Oxidative stress in a model of toxic demyelination in rat brain: the effect of piracetam and vinpocetine.

Authors:  Omar M E Abdel-Salam; Yasser A Khadrawy; Neveen A Salem; Amany A Sleem
Journal:  Neurochem Res       Date:  2011-03-30       Impact factor: 3.996

4.  The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide.

Authors:  C Kurz; I Ungerer; U Lipka; S Kirr; T Schütt; A Eckert; K Leuner; W E Müller
Journal:  Br J Pharmacol       Date:  2010-03-09       Impact factor: 8.739

5.  Piracetam improves mitochondrial dysfunction following oxidative stress.

Authors:  Uta Keil; Isabel Scherping; Susanne Hauptmann; Katin Schuessel; Anne Eckert; Walter E Müller
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 6.  Microstates in resting-state EEG: current status and future directions.

Authors:  Arjun Khanna; Alvaro Pascual-Leone; Christoph M Michel; Faranak Farzan
Journal:  Neurosci Biobehav Rev       Date:  2014-12-17       Impact factor: 8.989

Review 7.  Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease.

Authors:  Gunter P Eckert; Kathrin Renner; Schamim H Eckert; Janett Eckmann; Stephanie Hagl; Reham M Abdel-Kader; Christopher Kurz; Kristina Leuner; Walter E Muller
Journal:  Mol Neurobiol       Date:  2012-05-03       Impact factor: 5.590

Review 8.  Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspects.

Authors:  Walter E Müller; Anne Eckert; Christopher Kurz; Gunter Peter Eckert; Kristina Leuner
Journal:  Mol Neurobiol       Date:  2010-05-12       Impact factor: 5.590

9.  Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam.

Authors:  Kristina Leuner; Christopher Kurz; Giorgio Guidetti; Jean-Marc Orgogozo; Walter E Müller
Journal:  Front Neurosci       Date:  2010-09-07       Impact factor: 4.677

Review 10.  Biological approaches to aphasia treatment.

Authors:  Steven L Small; Daniel A Llano
Journal:  Curr Neurol Neurosci Rep       Date:  2009-11       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.